Neoleukin Therapeutics : Corporate Presentation January 2022

Corporate Presentation

January 2022

@Neoleukin Therapeutics. All Rights Reserved.

Forward Looking Statements

Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, properties of its product candidates, availability of data, the use and sufficiency of its cash resources and other statements containing the words

"anticipate," "believe," "expect," "may," "plan," "project," "potential," "will," "would," "could," "continue," and similar expressions.

These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any product candidates and the potential safety, efficacy or clinical utility of or any product candidates; further impacts of COVID-19 on our operations; and other factors discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2021 as filed with the Securities and Exchange Commission. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained in its Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2021, Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent reports, filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2	@Neoleukin Therapeutics. All Rights Reserved.

Key Company Highlights

De novo Protein Platform

Neoleukin's computational protein design method for creating cytokine mimetics has the potential to overcome biological limitations of natural proteins.

Solid

tumors

Heme

malignancies

Combination

approaches

Large Market in I/O Asset

Sales of the top 3 immunotherapy drugs totaled $25M in 2020, which represented compound annual growth of 36% over the prior 3 years.

Proven Mechanism of Action in IL-2

Aldesleukin (rhIL-2) is approved for the treatment of metastatic renal cell carcinoma and melanoma. Neoleukin's NL-201 is designed to stimulate an immunological response with potentially greater selectivity and less toxicity.

Data in 2022

Initiated phase 1 clinical trial for NL-201 in 2021.

Interim data is expected in 2022.

3	@Neoleukin Therapeutics. All Rights Reserved.

Building a Neoleukin™ Cytokine Mimetic

IL-2Ralpha		IL-2
IL-2
IL-2R	IL-2R
beta	gamma	IL-2	NL-201	NL-201

1	2	3	4
Develop an accurate	Identify regions of	Design an idealized	Assign optimal amino
structural model of target	intermolecular contact	topology	acid sequences

4	@Neoleukin Therapeutics. All Rights Reserved.

Pipeline
			Preclinical
Program	Mechanism	Discovery	Development	Phase 1	Anticipated Milestone / Status
	IL-2/15 Agonist				Ph. 1 Interim Data - 2022
	Solid Tumors
NL-201
Oncology	IL-2/15 Agonist				Ph. 1 Initiation - 2022
Heme Malignancies
Neo-202	Next-genIL-2/15 Agonist
Neo-5171	IL-2/15 Antagonist				Pre-clinical data disclosed Q4 2021
Autoimmune / Inflammatory
	Conditions
Inflammation
Neo-TRA	T-reg Agonist
Autoimmune / Inflammatory
	Conditions

NL-201 is believed to be the 1st de novo protein in clinic

5	@Neoleukin Therapeutics. All Rights Reserved.